Iovance Biotherapeutics, Inc. (IOVA)
$14.56-0.41%Close
BUYRECOVERY · day 36
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV5.2%–448.1%
- Market cap
- $6.5B
- Beta
- 0.76
- P/E (TTM)
- -18.51
- IV-%ile
- 41
- IV ATM
- 93.0%
- Short % float
- 16.71%
- Days to cover
- 2.8
- SI change
- -25.6%
- 1W
- +2.90%
- 1M
- +69.30%
- vs SPY 1W
- +2.48%
- vs SPY 1M
- +67.24%
Industry peers
FMP comparable companies · ranked by market cap
- BNTXSELLBioNTech SE$24.4BRECOVERYQ 35$96.96-1.16%
- GMABBUYGenmab A/S$22.8BBULLQ 21$37.07+0.81%
- IBRXBUYImmunityBio, Inc.$11.0BRECOVERYQ 8$10.51-3.71%
- LEGNSELLLegend Biotech Corporation$3.4BRECOVERYQ 2$18.62-4.40%
- IMNMSELLImmunome, Inc.$1.9BCRISISQ 18$19.55-2.05%
- IMCRSELLImmunocore Holdings plc$1.5BBEARQ 2$29.39-1.19%
- REPLSELLReplimune Group, Inc.$1.1BRECOVERYQ 14$13.42-2.61%
- STTKSELLShattuck Labs, Inc.$540MCRISISQ 5$5.97+2.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on IOVA?
- LOPJLB’s latest quantitative signal on Iovance Biotherapeutics, Inc. (IOVA) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is IOVA in?
- Iovance Biotherapeutics, Inc. (IOVA) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Iovance Biotherapeutics, Inc. (IOVA) do?
- Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, …